This article is more than 5 years old. Information may no longer be current.

CASES-PMS

Carotid Artery Stenting With Emboli Protection Surveillance — Post-Marketing Study

Issue: August 2010

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Study assessed relationship between experience level of operators and event rates in patients with de novo atherosclerotic or post-endarterectomy restenotic obstructive lesions.

Design: prospective
Patients: 1,492
Centers: 73
Country: United States

RESULTS: The primary endpoint was a composite of 30-day major adverse events, which included death, any stroke or MI. The rate of the primary endpoint was 5%, which met criteria for noninferiority to the prespecified objective performance criteria set by the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial. The 1-year cumulative percentage of major adverse events was 12.5%, and all strokes to 30 days plus ipsilateral stroke between 31 and 360 days were similar in the CASES-PMS trial (5.4%) vs. the SAPPHIRE cohort (4.9%).

Published in: J Am Coll Cardiol. 2010;56:49-57.

Click here to read more about the CASES-PMS trial.